Cargando…

Structural basis for PPAR partial or full activation revealed by a novel ligand binding mode

The peroxisome proliferator-activated receptors (PPARs) are nuclear receptors involved in the regulation of the metabolic homeostasis and therefore represent valuable therapeutic targets for the treatment of metabolic diseases. The development of more balanced drugs interacting with PPARs, devoid of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Capelli, Davide, Cerchia, Carmen, Montanari, Roberta, Loiodice, Fulvio, Tortorella, Paolo, Laghezza, Antonio, Cervoni, Laura, Pochetti, Giorgio, Lavecchia, Antonio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2016
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5052532/ https://www.ncbi.nlm.nih.gov/pubmed/27708429 http://dx.doi.org/10.1038/srep34792

Ejemplares similares

Screening of saponins and sapogenins from Medicago species as potential PPARγ agonists and X-ray structure of the complex PPARγ/caulophyllogenin
por: Montanari, Roberta, et al.
Publicado: (2016)

Betulinic acid is a PPARγ antagonist that improves glucose uptake, promotes osteogenesis and inhibits adipogenesis
por: Brusotti, Gloria, et al.
Publicado: (2017)

Beyond the Canonical Endocannabinoid System. A Screening of PPAR Ligands as FAAH Inhibitors
por: Brunetti, Leonardo, et al.
Publicado: (2020)

Bone-Seeking Matrix Metalloproteinase Inhibitors for the Treatment of Skeletal Malignancy
por: Laghezza, Antonio, et al.
Publicado: (2020)

Chiral phenoxyacetic acid analogues inhibit colon cancer cell proliferation acting as PPARγ partial agonists
por: Sabatino, Lina, et al.
Publicado: (2019)

Combining fatty acid amide hydrolase (FAAH) inhibition with peroxisome proliferator-activated receptor (PPAR) activation: a new potential multi-target therapeutic strategy for the treatment of Alzheimer’s disease
por: Brunetti, Leonardo, et al.
Publicado: (2019)

Sulfonimide and Amide Derivatives as Novel PPARα Antagonists: Synthesis, Antiproliferative Activity, and Docking Studies
por: Ammazzalorso, Alessandra, et al.
Publicado: (2020)

Biological Screening and Crystallographic Studies of Hydroxy γ-Lactone Derivatives to Investigate PPARγ Phosphorylation Inhibition
por: Capelli, Davide, et al.
Publicado: (2023)

Novel Benzylidene Thiazolidinedione Derivatives as Partial PPARγ Agonists and their Antidiabetic Effects on Type 2 Diabetes
por: Yasmin, Sabina, et al.
Publicado: (2017)

A New Series of Aryloxyacetic Acids Endowed with Multi-Target Activity towards Peroxisome Proliferator-Activated Receptors (PPARs), Fatty Acid Amide Hydrolase (FAAH), and Acetylcholinesterase (AChE)
por: Leuci, Rosalba, et al.
Publicado: (2022)

Natural Compounds for the Prevention and Treatment of Cardiovascular and Neurodegenerative Diseases
por: Leuci, Rosalba, et al.
Publicado: (2020)

(2-Aminobenzothiazole)-Methyl-1,1-Bisphosphonic Acids: Targeting Matrix Metalloproteinase 13 Inhibition to the Bone
por: Laghezza, Antonio, et al.
Publicado: (2021)

Dual targeting of cancer-related human matrix metalloproteinases and carbonic anhydrases by chiral N-(biarylsulfonyl)-phosphonic acids
por: Luisi, Grazia, et al.
Publicado: (2017)

Structural Basis for PPARs Activation by The Dual PPARα/γ Agonist Sanguinarine: A Unique Mode of Ligand Recognition
por: Tian, Siyu, et al.
Publicado: (2021)

Derivatives of Tenuazonic Acid as Potential New Multi-Target Anti-Alzheimer’s Disease Agents
por: Poliseno, Viviana, et al.
Publicado: (2021)

A compound-based proteomic approach discloses 15-ketoatractyligenin methyl ester as a new PPARγ partial agonist with anti-proliferative ability
por: Vasaturo, Michele, et al.
Publicado: (2017)

In Silico Drug Design and Discovery: Big Data for Small Molecule Design
por: Cerchia, Carmen, et al.
Publicado: (2022)

Single-Nucleotide Polymorphism of PPARγ, a Protein at the Crossroads of Physiological and Pathological Processes
por: Petrosino, Maria, et al.
Publicado: (2017)

Novel Phenothiazine/Donepezil-like Hybrids Endowed with Antioxidant Activity for a Multi-Target Approach to the Therapy of Alzheimer’s Disease
por: Carocci, Alessia, et al.
Publicado: (2022)

Exploring Structural Relationships between Bioactive and Commercial Chemical Space and Developing Target Hypotheses for Compound Acquisition
por: Cerchia, Carmen, et al.
Publicado: (2017)

Natural Scaffolds with Multi-Target Activity for the Potential Treatment of Alzheimer’s Disease
por: Piemontese, Luca, et al.
Publicado: (2018)

Structural basis for ligand binding modes of CTP synthase
por: Zhou, Xian, et al.
Publicado: (2021)

Surface Plasmon Resonance as a Tool for Ligand Binding Investigation of Engineered GPR17 Receptor, a G Protein Coupled Receptor Involved in Myelination
por: Capelli, Davide, et al.
Publicado: (2020)

Ligand-based chemoinformatic discovery of a novel small molecule inhibitor targeting CDC25 dual specificity phosphatases and displaying in vitro efficacy against melanoma cells
por: Capasso, Alessandra, et al.
Publicado: (2015)

Structural basis of ligand binding modes of human EAAT2
por: Zhang, Zhenglai, et al.
Publicado: (2022)

The Molecular Basis of PPAR Function
por: Barak, Yaacov, et al.
Publicado: (2010)

Structural basis for the inhibitory effects of a novel reversible covalent ligand on PPARγ phosphorylation
por: Jang, Jun Young, et al.
Publicado: (2019)

PPAR Ligands for Cancer Chemoprevention
por: Yasui, Yumiko, et al.
Publicado: (2008)

Nutraceuticals as Ligands of PPARγ
por: Penumetcha, Meera, et al.
Publicado: (2012)

Structural basis of ligand binding modes at the neuropeptide Y Y(1) receptor
por: Yang, Zhenlin, et al.
Publicado: (2018)

Structural basis of ligand binding modes at the human formyl peptide receptor 2
por: Chen, Tong, et al.
Publicado: (2020)

Selective inhibition of matrix metalloproteinase-2 in the multiple myeloma-bone microenvironment
por: Shay, Gemma, et al.
Publicado: (2017)

Novel Reversible Inhibitors of Xanthine Oxidase Targeting the Active Site of the Enzyme
por: Rullo, Rosario, et al.
Publicado: (2023)

Publisher Correction: Structural basis for the inhibitory effects of a novel reversible covalent ligand on PPARγ phosphorylation
por: Jang, Jun Young, et al.
Publicado: (2019)

Discovery of Novel Chemical Series of OXA-48 β-Lactamase Inhibitors by High-Throughput Screening
por: Garofalo, Barbara, et al.
Publicado: (2021)

Effects of PPARγ Ligands on Leukemia
por: Tabe, Yoko, et al.
Publicado: (2012)

Gastrointestinal Cytoprotection by PPARγ Ligands
por: Naito, Yuji, et al.
Publicado: (2010)

A Reexamination of the PPAR-α Activation Mode of Action as a Basis for Assessing Human Cancer Risks of Environmental Contaminants
por: Guyton, Kathryn Z., et al.
Publicado: (2009)

Emerging PPARγ-Independent Role of PPARγ Ligands in Lung Diseases
por: Kulkarni, Ajit A., et al.
Publicado: (2012)

Identification of a novel selective PPARγ ligand with a unique binding mode and improved therapeutic profile in vitro
por: Yi, Wei, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_fn20tsap8ig4bjm9rbf7f23qpa